Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI

NCT06201351 — Unknown, 60 participants, West China Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction Magnetic Resonance Imaging (MRI)

Registry	NCT06201351
Status	Unknown
Study type	Observational
Enrollment	60 (Estimated)
Sponsor	West China Hospital (Other)
Conditions	High-grade Glioma
Interventions	adaptive radiotherapy (Device)
Dates	start 2024-01-01 (estimated), primary completion 2025-12-01 (estimated), completion 2026-09-30 (estimated), first posted 2024-01-11, last updated 2024-01-11
Locations	1 site in China

-Summary

The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.

Expand all sections · Collapse all

+Detailed description

To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The relationship between changes and patient survival was analyzed.A predictive model was established to provide individualized adaptive radiotherapy for patients.

+Arms and interventions

Arm	Type	Interventions	Description
Adaptive radiotherapy group		Device: adaptive radiotherapy	MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.

adaptive radiotherapy (Device), also known as ART: MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.

+Outcome measures

Primary outcomes

Homogeneity index [up to 2 weeks]: HI: Homogeneity index. Dosimetric change
conformity index [up to 2 weeks]: CI: conformity index. Dosimetric change
Anatomic change [up to 2 weeks]: Dmax Volume

Secondary outcomes

progression-free survival (PFS) [assessed up to 12 months]: progression-free survival

+Eligibility

Sex: All, ages: 18 Years to 70 Years

Inclusion Criteria:

1. Age ≥18 years old;
2. High-grade glioma was confirmed by pathology after surgery;
3. ECOG score 0-2 points;
4. Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
5. Baseline data available.

Exclusion Criteria:

1. The pathological diagnosis is not clear;
2. No synchronous chemotherapy/adjuvant chemotherapy \&amp;lt; 6 cycles;
3. There are other malignant tumors;
4. Previously radiotherapy to the head;
5. Interruption of radiotherapy for more than 5 days;
6. Failure to collect baseline data.

+Locations (1)

Facility	City	Country	Status
West China Hospital	Chengdu, Sichuan	China

+Publications

Results publication: He S, Yu H, Yang Y, Mao Q, Wang X, Zeng Y, Wang F, Liu M, Li Y, Gao K, Peng X, Liu Y, Ai P. Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI. Cancer Med. 2026 Sep;15(9):e72225. doi: 10.1002/cam4.72225. PMID 42675793